AbbVie to Bolster Immunity Illness Drug Pipeline with Landos Deal
March 25 Reuters AbbVie will buy drug developer Landos Biopharma for up to 212 million as the Humiramaker aims to expand its pipeline of medicines to treat immune systemrelated illnesses, the companies said on Monday. Landos is currently conducting a midstage study of its lead experimental drug NX13 in a type of an inflammatory bowel disease called […]